Sorrento Therapeutics (SRNE) to Release Earnings on Tuesday

Sorrento Therapeutics (NASDAQ:SRNE) is projected to release its resultson Tuesday, May 12th. Analysts expect Sorrento Therapeutics to post earnings of ($0.3650) per share and revenue of $8.3740 million for the quarter.

Sorrento Therapeutics Stock Performance

Sorrento Therapeutics stock traded down $0.00 during midday trading on Tuesday, hitting $0.00. 20,039 shares of the company were exchanged, compared to its average volume of 316,793. The firm has a market capitalization of $385,896.00, a PE ratio of 0.00 and a beta of 0.30. Sorrento Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.10.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of therapies in immuno-oncology, inflammatory diseases and pain management. Leveraging proprietary antibody, small molecule and cell therapy platforms, Sorrento aims to advance next-generation treatment candidates that address unmet medical needs in oncology and chronic pain without reliance on traditional opioids.

The company’s immuno-oncology pipeline encompasses monoclonal antibodies, antibody-drug conjugates and engineered cell therapies designed to target solid tumors and hematologic malignancies.